Macedo C S, Silva M D, Spadella C T, Breim L C, Capeletti S, Mercadante M C, Hernandes D, Macedo A R
Departamento de Pediatria, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, SP, Brasil.
Braz J Med Biol Res. 1996 Oct;29(10):1329-35.
Acarbose is a competitive inhibitor of the intestinal alpha-glycosidases, that can delay absorption of intestinal carbohydrates causing their malabsorption. In the present paper we studied the effects of insulin, acarbose and their association on glomerular basement membrane thickening in alloxan-diabetic rats. Twenty-five male and female Wistar rats, approximately 3 months old at the beginning of the experiment, were assigned randomly to each of five experimental groups: normal control rats, alloxan-diabetic control rats, alloxan-diabetic rats treated with acarbose, alloxan-diabetic rats treated with insulin, and alloxan-diabetic rats treated with insulin plus acarbose. Alloxan was administered in a single i.v. dose of 442 mg/kg body weight. Insulin was given subcutaneously at doses of 18 to 30 IU/kg corrected daily on the basis of glycosuria and ketonuria. Acarbose was given mixed with rat chow in a dose of 50 mg/100 g chow. Body weight, water and food intake and diuresis, as well as blood and urine glucose were determined after 1, 3, 6, 9, and 12 months of treatment. Glomerular basement membrane (GBM) thickening was determined by electron microscopy at the same times. Clear clinical and laboratory signs of severe diabetes, with blood glucose levels above 200 mg/dl and urine glucose above 3000 mg/dl, were observed in all alloxan-diabetic control rats, in all periods of follow-up, whereas administration of insulin or acarbose reduced the blood glucose levels of treated groups. The most satisfactory control of blood and urine glucose was observed in animals treated with both insulin and acarbose. However, diarrhea was observed in diabetic rats treated with acarbose associated or not with insulin. GBM thickening was correlated with age in all groups. Beginning at six months after diabetes induction, the GBM of untreated diabetic rats was significantly thicker (mean +/- SEM, 4.446 +/- 0.45 mm) than that of normal rats (2.977 +/- 0.63mm). Both insulin and acarbose prevented GBM thickening and their combination induced thickening similar to the age dependent thickening observed for normal rats of the same age. We conclude that acarbose when combined with insulin may be a good option in the control of diabetes and its renal complications.
阿卡波糖是肠道α-糖苷酶的竞争性抑制剂,可延迟肠道碳水化合物的吸收,导致其吸收不良。在本文中,我们研究了胰岛素、阿卡波糖及其联合使用对四氧嘧啶糖尿病大鼠肾小球基底膜增厚的影响。25只雄性和雌性Wistar大鼠,实验开始时约3个月大,随机分为五个实验组:正常对照大鼠、四氧嘧啶糖尿病对照大鼠、用阿卡波糖治疗的四氧嘧啶糖尿病大鼠、用胰岛素治疗的四氧嘧啶糖尿病大鼠以及用胰岛素加阿卡波糖治疗的四氧嘧啶糖尿病大鼠。四氧嘧啶以442mg/kg体重的单次静脉注射剂量给药。胰岛素根据糖尿和酮尿情况每天皮下注射18至30IU/kg的校正剂量。阿卡波糖以50mg/100g食物的剂量与大鼠食物混合给药。在治疗1、3、6、9和12个月后测定体重、水和食物摄入量、尿量以及血糖和尿糖。同时通过电子显微镜测定肾小球基底膜(GBM)增厚情况。在所有四氧嘧啶糖尿病对照大鼠的随访期间,均观察到严重糖尿病的明显临床和实验室体征,血糖水平高于200mg/dl,尿糖高于3000mg/dl,而胰岛素或阿卡波糖的给药降低了治疗组的血糖水平。在用胰岛素和阿卡波糖治疗的动物中观察到对血糖和尿糖最满意的控制。然而,在用阿卡波糖治疗的糖尿病大鼠中,无论是否联合胰岛素,均观察到腹泻。GBM增厚与所有组的年龄相关。在糖尿病诱导6个月后,未治疗的糖尿病大鼠的GBM(平均±SEM,4.446±0.45mm)明显厚于正常大鼠(2.977±0.63mm)。胰岛素和阿卡波糖均能预防GBM增厚,它们的联合使用诱导的增厚类似于同年龄正常大鼠观察到的与年龄相关的增厚。我们得出结论,阿卡波糖与胰岛素联合使用可能是控制糖尿病及其肾脏并发症的一个好选择。